After these results, on March 8, 2019, the FDA granted accelerated approval to atezolizumab in combination with nab-paclitaxel for patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 tumor-infiltrating ICs covering ≥ 1% of the tumor area, as determined by the Ventana PD-L1 (SP142) assay (66). The gene discussed is CD274; the disease is neoplasm.